Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
CC transcript
Appointed director
MANNKIND CORP (MNKD) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/26/2021 GN MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche
04/19/2021 GN Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
03/16/2021 GN MannKind Announces Closing of Initial Purchasers' Option to Purchase Additional Convertible Senior Notes
03/10/2021 GN MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference
03/02/2021 GN MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
03/02/2021 GN MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering
02/18/2021 GN MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
01/04/2021 GN MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference
12/07/2020 GN MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.
11/19/2020 GN MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics
11/04/2020 GN MannKind Corporation Reports 2020 Third Quarter Financial Results
08/31/2020 GN Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety
08/07/2020 GN MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020
08/05/2020 GN MannKind Corporation Reports 2020 Second Quarter Financial Results
07/29/2020 GN MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020
07/20/2020 GN Alejandro Galindo Joins MannKind as Chief Commercial Officer
06/17/2020 GN MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference
06/15/2020 GN MannKind Presents Positive Original Analyses of Afrezza® Clinical Data at  American Diabetes Association (ADA) 80th Scientific Sessions
06/13/2020 GN Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM
04/29/2020 GN MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020
04/15/2020 GN MannKind Receives Forgivable Loan under the Paycheck Protection Program
03/24/2020 GN Jennifer Grancio Appointed to MannKind Board of Directors
02/24/2020 GN MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference
12/20/2019 GN Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes
11/29/2019 GN MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference
11/04/2019 GN MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics
10/30/2019 GN MannKind Corporation to Hold 2019 Third Quarter Financial Results Conference Call on November 6, 2019
09/26/2019 GN MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference
09/19/2019 GN MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD
08/30/2019 GN MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference
07/31/2019 GN Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients Opens Enrollment for Cohort 3
07/15/2019 GN MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients
07/11/2019 GN MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules
06/09/2019 GN MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy